{
  "symbol": "UNH",
  "year": 2023,
  "Period": "Q1",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1864,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.19
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) September 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 38,915 $ 23,365 Short-term investments 5,182 4,546 Accounts receivable, net 20,673 17,681 Other current receivables, net 17,752 12,769 Assets under management 3,616 4,087 Prepaid expenses and other current assets 5,767 6,621 Total current assets 91,905 69,069 Long-term investments 45,474 43,728 Property, equipment and capitalized software, net 11,070 10,128 Goodwill 101,703 93,352 Other intangible assets, net 15,200 14,401 Other assets 16,711 15,027 Total assets $ 282,063 $ 245,705 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 32,792 $ 29,056 Accounts payable and accrued liabilities 31,164 27,715 Short-term borrowings and current maturities of long-term debt 5,290 3,110 Unearned revenues 15,311 3,075 Other current liabilities 29,622 26,281 Total current liabilities 114,179 89,237 Long-term debt, less current maturities 58,079 54,513 Deferred income taxes 2,210 2,769 Other liabilities 13,615 12,839 Total liabilities 188,083 159,358 Commitments and contingencies (Note 7) Redeemable noncontrolling interests 4,416 4,897 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 925 and 934 issued and outstanding 9 9 Retained earnings 93,173 86,156 Accumulated other comprehensive loss ( 8,688 ) ( 8,393 ) Nonredeemable noncontrolling interests 5,070 3,678 Total equity 89,564 81,450 Total liabilities, redeemable noncontrolling interests and equity $ 282,063 $ 245,705 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in millions, except per share data) 2023 2022 2023 2022 Revenues: Premiums $ 72,339 $ 64,491 $ 217,599 $ 192,457 Products 10,354 9,190 31,272 28,026 Services 8,671 6,700 25,414 19,717 Investment and other income 997 513 2,910 1,175 Total revenues 92,361 80,894 277,195 241,375 Operating costs: Medical costs 59,550 52,635 179,663 157,251 Operating costs 13,855 11,663 41,289 34,773 Cost of products sold 9,423 8,306 28,576 25,389 Depreciation and amortization 1,007 828 2,998 2,418 Total operating costs 83,835 73,432 252,526 219,831 Earnings from operations 8,526 7,462 24,669 21,544 Interest expense ( 834 ) ( 516 ) ( 2,416 ) ( 1,416 ) Earnings before income taxes 7,692 6,946 22,253 20,128 Provision for income taxes ( 1,654 ) ( 1,562 ) ( 4,784 ) ( 4,397 ) Net earnings 6,038 5,384 17,469 15,731 Earnings attributable to noncontrolling interests ( 197 ) ( 122 ) ( 543 ) ( 372 ) Net earnings attributable to UnitedHealth Group common shareholders $ 5,841 $ 5,262 16,926 $ 15,359 Earnings per share attributable to UnitedHealth Group common shareholders: Basic $ 6.31 $ 5.63 $ 18.20 $ 16.37 Diluted $ 6.24 $ 5.55 $ 18.01 $ 16.15 Basic weighted-average number of common shares outstanding 926 935 930 938 Dilutive effect of common share equivalents 10 13 10 13 Diluted weighted-average number of common shares outstanding 936 948 940 951 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 6 3 6 3 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2023 2022 2023 2022 Net earnings $ 6,038 $ 5,384 $ 17,469 $ 15,731 Other comprehensive loss: Gross unrealized losses on investment securities during the period ( 893 ) ( 1,471 ) ( 684 ) ( 4,825 ) Income tax effect 204 340 156 1,109 Total unrealized losses, net of tax ( 689 ) ( 1,131 ) ( 528 ) ( 3,716 ) Gross reclassification adjustment for net realized losses (gains) included in net earnings 7 138 ( 27 ) 134 Income tax effect ( 2 ) ( 32 ) 6 ( 31 ) Total reclassification adjustment, net of tax 5 106 ( 21 ) 103 Total foreign currency translation (losses) gains ( 354 ) ( 331 ) 254 ( 89 ) Other comprehensive loss ( 1,038 ) ( 1,356 ) ( 295 ) ( 3,702 ) Comprehensive income 5,000 4,028 17,174 12,029 Comprehensive income attributable to noncontrolling interests ( 197 ) ( 122 ) ( 543 ) ( 372 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 4,803 $ 3,906 $ 16,631 $ 11,657 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended September 30, (in millions) Shares Amount Net Unrealized Losses on Investments Foreign Currency Translation Losses Balance at June 30, 2023 927 $ 9 $ \u2014 $ 89,994 $ ( 2,643 ) $ ( 5,007 ) $ 5,015 $ 87,368 Net earnings 5,841 149 5,990 Other comprehensive loss ( 684 ) ( 354 ) ( 1,038 ) Issuances of common stock, and related tax effects 1 \u2014 395 395 Share-based compensation 235 235 Common share repurchases ( 3 ) \u2014 ( 588 ) ( 923 ) ( 1,511 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,739 ) ( 1,739 ) Redeemable noncontrolling interests fair value and other adjustments ( 42 ) ( 42 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 42 42 Distribution to nonredeemable noncontrolling interests ( 136 ) ( 136 ) Balance at September 30, 2023 925 $ 9 $ \u2014 $ 93,173 $ ( 3,327 ) $ ( 5,361 ) $ 5,070 $ 89,564 Balance at June 30, 2022 935 $ 10 $ \u2014 $ 80,540 $ ( 2,165 ) $ ( 5,565 ) $ 3,385 $ 76,205 Net earnings 5,262 99 5,361 Other comprehensive loss ( 1,025 ) ( 331 ) ( 1,356 ) Issuances of common stock, and related tax effects 2 \u2014 294 294 Share-based compensation 163 163 Common share repurchases ( 2 ) \u2014 ( 462 ) ( 538 ) ( 1,000 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,542 ) ( 1,542 ) Redeemable noncontrolling interests fair value and other adjustments 5 5 Acquisition and other adjustments of nonredeemable noncontrolling interests 32 32 Distribution to nonredeemable noncontrolling interests ( 98 ) ( 98 ) Balance at September 30, 2022 935 $ 10 $ \u2014 $ 83,722 $ ( 3,190 ) $ ( 5,896 ) $ 3,418 $ 78,064 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive (Loss) Income Nonredeemable Noncontrolling Interests Total Equity Nine months ended September 30, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2023 934 $ 9 $ \u2014 $ 86,156 $ ( 2,778 ) $ ( 5,615 ) $ 3,678 $ 81,450 Net earnings 16,926 401 17,327 Other comprehensive (loss) income ( 549 ) 254 ( 295 ) Issuances of common stock, and related tax effects 4 \u2014 963 963 Share-based compensation 833 833 Common share repurchases ( 13 ) \u2014 ( 1,663 ) ( 4,886 ) ( 6,549 ) Cash dividends paid on common shares ($ 5.41 per share) ( 5,023 ) ( 5,023 ) Redeemable noncontrolling interests fair value and other adjustments ( 133 ) ( 133 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 1,339 1,339 Distribution to nonredeemable noncontrolling interests ( 348 ) ( 348 ) Balance at September 30, 2023\n) $ 20,128 15 Table of Contents ITEM\u00a02.",
      "score": 0.9977
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of September\u00a030, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): September 30, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 971 $ 419 $ (3,408) $ (7,067) 1 486 209 (1,758) (3,846) (1) (486) (193) 1,858 4,635 (2) (971) (386) 3,800 10,274 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of September\u00a030, 2023 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): September 30, 2023 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 971 $ 419 $ (3,408) $ (7,067) 1 486 209 (1,758) (3,846) (1) (486) (193) 1,858 4,635 (2) (971) (386) 3,800 10,274 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    }
  ],
  "top_negative": [
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    },
    {
      "sent": "By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify.",
      "score": -0.7184
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We expect overall spending on health care to continue to grow in the future due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs.",
    "Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans."
  ]
}